Report overview
This report contains market size and forecasts of Rituximab Biosimilars in global, including the following market information:
Global Rituximab Biosimilars Market Revenue, 2018-2023, 2023-2030, ($ millions)
Global Rituximab Biosimilars Market Sales, 2018-2023, 2023-2030, (K Units)
Global top five Rituximab Biosimilars companies in 2022 (%)
The global Rituximab Biosimilars market was valued at million in 2022 and is projected to reach US$ million by 2030, at a CAGR of % during the forecast period 2023-2030.
The U.S. Market is Estimated at $ Million in 2022, While China is Forecast to Reach $ Million by 2030.
500mg Segment to Reach $ Million by 2030, with a % CAGR in next six years.
The global key manufacturers of Rituximab Biosimilars include Amgen, AryoGen Pharmed, Biocad, Cadila Pharmaceuticals, Celltrion, Dr Reddy?s Laboratories, Teva, Hetero Group and Innovent Biologics, etc. In 2022, the global top five players have a share approximately % in terms of revenue.
We surveyed the Rituximab Biosimilars manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Rituximab Biosimilars Market, by Type, 2018-2023, 2023-2030 ($ Millions) & (K Units)
Global Rituximab Biosimilars Market Segment Percentages, by Type, 2022 (%)
500mg
100mg
Other
Global Rituximab Biosimilars Market, by Application, 2018-2023, 2023-2030 ($ Millions) & (K Units)
Global Rituximab Biosimilars Market Segment Percentages, by Application, 2022 (%)
Hospital Pharmacy
Retail Pharmacy
Global Rituximab Biosimilars Market, By Region and Country, 2018-2023, 2023-2030 ($ Millions) & (K Units)
Global Rituximab Biosimilars Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Rituximab Biosimilars revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies Rituximab Biosimilars revenues share in global market, 2022 (%)
Key companies Rituximab Biosimilars sales in global market, 2018-2023 (Estimated), (K Units)
Key companies Rituximab Biosimilars sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Amgen
AryoGen Pharmed
Biocad
Cadila Pharmaceuticals
Celltrion
Dr Reddy?s Laboratories
Teva
Hetero Group
Innovent Biologics
Intas Biopharmaceuticals
Mylan
Probiomed
TRPharma
Zenotech Laboratories
